Organon & Co. Plans Quarterly Dividend of $0.02 (NYSE:OGN)

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, February 12th. Stockholders of record on Monday, February 23rd will be paid a dividend of 0.02 per share on Thursday, March 12th. This represents a c) dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Monday, February 23rd.

Organon & Co. has a dividend payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.1%.

Organon & Co. Price Performance

Shares of OGN stock opened at $7.08 on Friday. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $17.23. The company has a market capitalization of $1.84 billion, a P/E ratio of 3.69, a P/E/G ratio of 1.66 and a beta of 0.58. The stock has a 50 day moving average of $7.88 and a two-hundred day moving average of $8.61. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period last year, the business earned $0.90 earnings per share. As a group, equities analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Key Organon & Co. News

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Management gave FY2026 revenue guidance of about $6.2 billion, a touch above the Street, which provides a modest upside case versus analyst revenue expectations. Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
• Neutral Sentiment: Board declared a quarterly dividend of $0.02/share (ex-div Feb 23, pay Mar 12), yielding ~1.1%; the payout is modest and follows last year’s cut, so it’s unlikely to materially change investor sentiment on its own.
• Neutral Sentiment: Company released the Q4 results, slide deck and earnings-call transcript for investors to review operational and segment detail. Use these primary materials to check management’s commentary on brand trends and cost actions. Q4 Press Release / Slide Deck Earnings Call Transcript
• Negative Sentiment: Q4 EPS ($0.63) and revenue (~$1.51B) missed consensus and were down year-over-year, driving near-term pressure on the stock as the core business shows contraction. Organon (OGN) Misses Q4 Earnings and Revenue Estimates MarketBeat: Q4 Results
• Negative Sentiment: Analyst commentary highlights structural risks: declining legacy brands, flat biosimilar growth, underwhelming Women’s Health performance and heavy net debt (~$8B) that constrain capital allocation and M&A — a material longer-term headwind. Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
• Negative Sentiment: Broker/coverage takes and earnings-call notes point to rising execution and market risks despite some stability — reinforcing investor caution until clearer signs of revenue stabilization or debt reduction emerge. Organon Earnings Call Balances Stability With Rising Risks

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.